PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2021 to 2027

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

It has been developed for several indications. The most important thing is cancer treatment. PARP is an attractive target for cancer treatment as many forms of cancer rely more on PARP than normal cells. PARP inhibitors appear to improve progression-free survival in women with ovarian cancer sensitive to recurrent platinum, as evidenced primarily by olaparibs added to existing treatments.

PARP (Poly ADP-Ribose Polymerase) Inhibitor market size was US$ 3917.3 million and is forecast to 21490 million US in 2027, growing at a CAGR of 32% during the 2021-2027.

Segment by Type

• Lynparza
• Zejula
• Rubraca
• Talzenna
• Other

Segment by Application

• Ovarian Cancer
• Breast Cancer
• Other

By Company

• AstraZeneca
• Tesaro
• Merck & Co
• Clovis Oncology
• Pfizer

Scope of the Report

The research study analyzes the global PARP (Poly ADP-Ribose Polymerase) Inhibitor industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report

1. What was the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2021-2027).

2. What will be the CAGR of PARP (Poly ADP-Ribose Polymerase) Inhibitor Market during the forecast period (2021-2027)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2021-2027).
4. Which manufacturer/vendor/players in the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.